Search by Drug Name or NDC
NDC 42799-0963-02 venlafaxine hydrochloride, extended release 225 mg/1 Details
venlafaxine hydrochloride, extended release 225 mg/1
venlafaxine hydrochloride, extended release is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Edenbridge Pharmaceuticals LLC.. The primary component is VENLAFAXINE HYDROCHLORIDE.
MedlinePlus Drug Summary
Venlafaxine is used to treat depression. Venlafaxine extended-release (long-acting) capsules are also used to treat generalized anxiety disorder (GAD; excessive worrying that is difficult to control), social anxiety disorder (extreme fear of interacting with others or performing in front of others that interferes with normal life), and panic disorder (sudden, unexpected attacks of extreme fear and worry about these attacks). Venlafaxine is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). It works by increasing the amounts of serotonin and norepinephrine, natural substances in the brain that help maintain mental balance.
Related Packages: 42799-0963-02Last Updated: 04/14/2024
MedLinePlus Full Drug Details: Venlafaxine
Product Information
| NDC | 42799-0963 |
|---|---|
| Product ID | 42799-963_9c56448e-7291-4e1e-a260-5c22f01c3448 |
| Associated GPIs | |
| GCN Sequence Number | 064447 |
| GCN Sequence Number Description | venlafaxine HCl TAB ER 24 225 MG ORAL |
| HIC3 | H7C |
| HIC3 Description | SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS) |
| GCN | 14354 |
| HICL Sequence Number | 008847 |
| HICL Sequence Number Description | VENLAFAXINE HCL |
| Brand/Generic | Generic |
| Proprietary Name | venlafaxine hydrochloride, extended release |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | venlafaxine hydrochloride, extended release |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 225 |
| Active Ingredient Units | mg/1 |
| Substance Name | VENLAFAXINE HYDROCHLORIDE |
| Labeler Name | Edenbridge Pharmaceuticals LLC. |
| Pharmaceutical Class | Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA209193 |
| Listing Certified Through | 2025-12-31 |
Package
NDC 42799-0963-02 (42799096302)
| NDC Package Code | 42799-963-02 |
|---|---|
| Billing NDC | 42799096302 |
| Package | 90 TABLET in 1 BOTTLE (42799-963-02) |
| Marketing Start Date | 2023-03-15 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 0.75344 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | VENLAFAXINE HCL ER 225 MG TAB |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |